The SIC found that the drug Lamictal, used to treat epilepsy and bipolar disorder, was sometimes sold for as much as 653% above its maximum set value.
The Superintendency of Industry and Commerce (SIC) fined Glaxosmithkline Colombia $ 678 million for exceeding the maximum sale price of one of its drugs. In this way, the company violated the provisions of article 1 of Circular 04 of 2012 of the National Commission for the Prices of Medicines and Medical Devices (CNPMDM).
The SIC found that the drug Lamictal, used to treat epilepsy and bipolar disorder, was sometimes sold for as much as 653% above its maximum set value.
The price increase occurred in the Lamictal presentations of 25, 50, 100, and 200 mg – tablet x 30.
"The sanction was imposed after verifying that said drug was marketed with this surcharge in the general health social security system, affecting not only public finances, but also the fundamental rights of patients and the market regulated by the State," he said. the SIC.
The sanction against Glaxosmithkline Colombia is of the first instance, and the remedies for reconsideration and appeal proceed.
